Cargando…

How to assess endoscopic disease activity in ulcerative colitis in 2022

Endoscopic remission currently represents an important therapeutic goal to reach in the management of patients with ulcerative colitis (UC). The diagnostic and prognostic role of endoscopy, which remains the gold standard for the assessment of disease activity, has been widely reported. Despite bein...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruscio, Mirko Di, Cedola, Marco, Mangone, Manuela, Brighi, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399578/
https://www.ncbi.nlm.nih.gov/pubmed/36061162
http://dx.doi.org/10.20524/aog.2022.0732
_version_ 1784772555292278784
author Ruscio, Mirko Di
Cedola, Marco
Mangone, Manuela
Brighi, Stefano
author_facet Ruscio, Mirko Di
Cedola, Marco
Mangone, Manuela
Brighi, Stefano
author_sort Ruscio, Mirko Di
collection PubMed
description Endoscopic remission currently represents an important therapeutic goal to reach in the management of patients with ulcerative colitis (UC). The diagnostic and prognostic role of endoscopy, which remains the gold standard for the assessment of disease activity, has been widely reported. Despite being unvalidated and suboptimal at measuring remission, the most widely used scoring system is the Mayo endoscopic subscore (MES). The UC Endoscopic Index of Severity and the UC Colonoscopic Index of Severity represent recent performing indices for the assessment of endoscopic disease activity in the field of white-light endoscopy. However, their use is still very limited, both in trials and clinical practice. The most recent Paddington international virtual chromoendoscopy score was the first validated index to assess vascular and mucosal features in UC using a virtual chromoendoscopy technique and showed good performance. This narrative review aims to describe these validated endoscopic scoring indices, focusing on the development methodology, and the strengths and weaknesses of each one in comparison with the MES for the assessment of UC activity.
format Online
Article
Text
id pubmed-9399578
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hellenic Society of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-93995782022-09-01 How to assess endoscopic disease activity in ulcerative colitis in 2022 Ruscio, Mirko Di Cedola, Marco Mangone, Manuela Brighi, Stefano Ann Gastroenterol Review Article Endoscopic remission currently represents an important therapeutic goal to reach in the management of patients with ulcerative colitis (UC). The diagnostic and prognostic role of endoscopy, which remains the gold standard for the assessment of disease activity, has been widely reported. Despite being unvalidated and suboptimal at measuring remission, the most widely used scoring system is the Mayo endoscopic subscore (MES). The UC Endoscopic Index of Severity and the UC Colonoscopic Index of Severity represent recent performing indices for the assessment of endoscopic disease activity in the field of white-light endoscopy. However, their use is still very limited, both in trials and clinical practice. The most recent Paddington international virtual chromoendoscopy score was the first validated index to assess vascular and mucosal features in UC using a virtual chromoendoscopy technique and showed good performance. This narrative review aims to describe these validated endoscopic scoring indices, focusing on the development methodology, and the strengths and weaknesses of each one in comparison with the MES for the assessment of UC activity. Hellenic Society of Gastroenterology 2022 2022-07-11 /pmc/articles/PMC9399578/ /pubmed/36061162 http://dx.doi.org/10.20524/aog.2022.0732 Text en Copyright: © Hellenic Society of Gastroenterology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Ruscio, Mirko Di
Cedola, Marco
Mangone, Manuela
Brighi, Stefano
How to assess endoscopic disease activity in ulcerative colitis in 2022
title How to assess endoscopic disease activity in ulcerative colitis in 2022
title_full How to assess endoscopic disease activity in ulcerative colitis in 2022
title_fullStr How to assess endoscopic disease activity in ulcerative colitis in 2022
title_full_unstemmed How to assess endoscopic disease activity in ulcerative colitis in 2022
title_short How to assess endoscopic disease activity in ulcerative colitis in 2022
title_sort how to assess endoscopic disease activity in ulcerative colitis in 2022
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399578/
https://www.ncbi.nlm.nih.gov/pubmed/36061162
http://dx.doi.org/10.20524/aog.2022.0732
work_keys_str_mv AT rusciomirkodi howtoassessendoscopicdiseaseactivityinulcerativecolitisin2022
AT cedolamarco howtoassessendoscopicdiseaseactivityinulcerativecolitisin2022
AT mangonemanuela howtoassessendoscopicdiseaseactivityinulcerativecolitisin2022
AT brighistefano howtoassessendoscopicdiseaseactivityinulcerativecolitisin2022